Literature DB >> 8644728

Characterization of the factor VIII defect in 147 patients with sporadic hemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies.

J Becker1, R Schwaab, A Möller-Taube, U Schwaab, W Schmidt, H H Brackmann, T Grimm, K Olek, J Oldenburg.   

Abstract

The clinical manifestation of hemophilia A is caused by a wide range of different mutations. In this study the factor VIII genes of 147 severe hemophilia A patients--all exclusively from sporadic families--were screened for mutations by use of the complete panel of modern DNA techniques. The pathogenous defect could be characterized in 126 patients (85.7 percent). Fifty-five patients (37.4 percent) showed a F8A-gene inversion, 47 (32.0 percent) a point mutation, 14 (9.5 percent) a small deletion, 8 (5.4 percent) a large deletion, and 2 (1.4 percent) a small insertion. Further, four (2.7 percent) mutations were localized but could not be sequenced yet. No mutation could be identified in 17 patients (11.6 percent). Sixteen (10.9 percent) of the identified mutations occurred in the B domain. Four of these were located in an adenosine nucleotide stretch at codon 1192, indicating a mutation hotspot. Somatic mosaicisms were detected in 3 (3.9 percent) of 76 patients, mothers, comprising 3 of 16 de novo mutations in the patients mothers. Investigation of family relatives allowed detection of a de novo mutation in 16 of 76 two-generation and 28 of 34 three-generation families. On the basis of these data, the male:female ratio of mutation frequencies (k) was estimated as k = 3.6. By use of the quotients of mutation origin in maternal grandfather to patients mother or to maternal grandmother, k was directly estimated as k = 15 and k = 7.5, respectively. Considering each mutation type separately, we revealed a mutation type-specific sex ratio of mutation frequencies. Point mutations showed a 5-to-10-fold-higher and inversions a >10-fold-higher mutation rate in male germ cells, whereas deletions showed a >5-fold-higher mutation rate in female germ cells. Consequently, and in accordance with the data of other diseases like Duchenne muscular dystrophy, our results indicate that at least for X-chromosomal disorders the male:female mutation rate of a disease is determined by its proportion of the different mutation types.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8644728      PMCID: PMC1914681     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  62 in total

1.  Inversions in the factor VIII gene in Spanish hemophilia A patients.

Authors:  E F Tizzano; M Domènech; C Altisent; J Tusell; M Baiget
Journal:  Blood       Date:  1994-06-15       Impact factor: 22.113

2.  Intron 22 inversions and haemophilia.

Authors:  P W Collins; P V Jenkins; E Goldman; C A Lee; K J Pasi
Journal:  Lancet       Date:  1994-03-26       Impact factor: 79.321

3.  Characterization of genetic defects of hemophilia A in patients of Chinese origin.

Authors:  S W Lin; S R Lin; M C Shen
Journal:  Genomics       Date:  1993-12       Impact factor: 5.736

4.  Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A.

Authors:  D Lakich; H H Kazazian; S E Antonarakis; J Gitschier
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

5.  Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition.

Authors:  E G Tuddenham; R Schwaab; J Seehafer; D S Millar; J Gitschier; M Higuchi; S Bidichandani; J M Connor; L W Hoyer; A Yoshioka
Journal:  Nucleic Acids Res       Date:  1994-09       Impact factor: 16.971

6.  On the origin of deletions and point mutations in Duchenne muscular dystrophy: most deletions arise in oogenesis and most point mutations result from events in spermatogenesis.

Authors:  T Grimm; G Meng; S Liechti-Gallati; T Bettecken; C R Müller; B Müller
Journal:  J Med Genet       Date:  1994-03       Impact factor: 6.318

7.  Factor VIII gene inversions causing severe hemophilia A originate almost exclusively in male germ cells.

Authors:  J P Rossiter; M Young; M L Kimberland; P Hutter; R P Ketterling; J Gitschier; J Horst; M A Morris; D J Schaid; P de Moerloose
Journal:  Hum Mol Genet       Date:  1994-07       Impact factor: 6.150

8.  Direct and indirect estimation of the sex ratio of mutation frequencies in hemophilia A.

Authors:  J Oldenburg; R Schwaab; T Grimm; K Zerres; P Hakenberg; H H Brackmann; K Olek
Journal:  Am J Hum Genet       Date:  1993-12       Impact factor: 11.025

9.  Haemophilia A diagnosis by simultaneous analysis of two variable dinucleotide tandem repeats within the factor VIII gene.

Authors:  M R Lalloz; R Schwaab; J H McVey; K Michaelides; E G Tuddenham
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

10.  Haemophilia A diagnosis by automated fluorescent DNA detection of ten factor VIII intron 13 dinucleotide repeat alleles.

Authors:  L Kochhan; M R Lalloz; J Oldenburg; J H McVey; K Olek; H H Brackmann; E G Tuddenham; R Schwaab
Journal:  Blood Coagul Fibrinolysis       Date:  1994-08       Impact factor: 1.276

View more
  15 in total

1.  Hardy, Weinberg and language impediments.

Authors:  J F Crow
Journal:  Genetics       Date:  1999-07       Impact factor: 4.562

2.  De novo facioscapulohumeral muscular dystrophy: frequent somatic mosaicism, sex-dependent phenotype, and the role of mitotic transchromosomal repeat interaction between chromosomes 4 and 10.

Authors:  S M van der Maarel; G Deidda; R J Lemmers; P G van Overveld; M van der Wielen; J E Hewitt; L Sandkuijl; B Bakker; G J van Ommen; G W Padberg; R R Frants
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

3.  Somatic mosaicism in hemophilia A: a fairly common event.

Authors:  M Leuer; J Oldenburg; J M Lavergne; M Ludwig; A Fregin; A Eigel; R Ljung; A Goodeve; I Peake; K Olek
Journal:  Am J Hum Genet       Date:  2001-06-14       Impact factor: 11.025

4.  Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B.

Authors:  P M Green; S Saad; C M Lewis; F Giannelli
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

5.  Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe hemophilia A: implications for genotyping.

Authors:  K Ogata; S R Selvaraj; H Z Miao; S W Pipe
Journal:  J Thromb Haemost       Date:  2011-06       Impact factor: 5.824

6.  Mutations in btk in patients with presumed X-linked agammaglobulinemia.

Authors:  M E Conley; D Mathias; J Treadaway; Y Minegishi; J Rohrer
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

7.  Proteolipoprotein gene analysis in 82 patients with sporadic Pelizaeus-Merzbacher Disease: duplications, the major cause of the disease, originate more frequently in male germ cells, but point mutations do not. The Clinical European Network on Brain Dysmyelinating Disease.

Authors:  C Mimault; G Giraud; V Courtois; F Cailloux; J Y Boire; B Dastugue; O Boespflug-Tanguy
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 8.  Understanding what determines the frequency and pattern of human germline mutations.

Authors:  Norman Arnheim; Peter Calabrese
Journal:  Nat Rev Genet       Date:  2009-07       Impact factor: 53.242

9.  Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution.

Authors:  O El-Maarri; A Olek; B Balaban; M Montag; H van der Ven; B Urman; K Olek; S H Caglayan; J Walter; J Oldenburg
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

10.  Identification of 31 novel mutations in the F8 gene in Spanish hemophilia A patients: structural analysis of 20 missense mutations suggests new intermolecular binding sites.

Authors:  Adoración Venceslá; María Angeles Corral-Rodríguez; Manel Baena; Mónica Cornet; Montserrat Domènech; Montserrat Baiget; Pablo Fuentes-Prior; Eduardo F Tizzano
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.